Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells.
Omar
O
Al Ustwani
Jawad
J
Francis
Paul K
PK
Wallace
Julian
J
Ambrus
Meir
M
Wetzler
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications / Q000473:pathology / Q000517:prevention & control*; D001374:Azacitidine / Q000627:therapeutic use; D001772:Blood Cell Count; D015536:Down-Regulation; D006801:Humans; D006816:Huntington Disease / Q000150:complications / Q000175:diagnosis / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology / Q000628:therapy; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000473:pathology*
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine
Blood. 2007 Aug 1;110(3):847-50
17412885
J Autoimmun. 2005 May;24(3):235-42
15848046
Lupus. 2007;16(5):374-7
17576742
Cytometry B Clin Cytom. 2009 Mar;76(2):69-78
18690669
BMC Immunol. 2009 Jan 27;10:5
19173720
Rheumatol Int. 2011 Sep;31(9):1219-25
20361330
Eur J Clin Invest. 2004 Oct;34(10):690-700
15473894
Eur J Immunol. 2003 Jan;33(1):215-23
12594850
Haematologica. 2008 Mar;93(3):381-9
18268282
Clin Immunol. 2008 May;127(2):151-7
18299252